INHIBITOR Therapeutics, Inc. is a publicly traded pharmaceutical company (OTCQB:INTI) focused on developing and commercializing innovative therapies for patients with cancer and non-cancerous proliferation disorders.

SUBA-Itraconazole, the company’s lead product candidate, is a patented, oral formulation of the currently FDA approved and marketed, well-understood, anti-fungal drug, itraconazole, which, when studied to treat patients with cancer, has demonstrated activity against multiple tumor types. INHIBITOR is developing SUBA-Itraconazole for late-stage, metastatic castrate-resistant prostate cancer (mCRPC) and late-stage non-squamous non-small cell lung cancer (NSCLC). INHIBITOR is the exclusive U.S. licensee for SUBA-Itraconazole for the treatment of certain cancers and non-cancerous proliferation disorders.

INHIBITOR’s lead programs are clinically de-risked due to itraconazole’s prior FDA approval (505(b)(2) pathway), with proven bioavailability, safety and anti-tumor efficacy previously demonstrated in an INHIBITOR clinical trial testing SUBA-Itraconazole in 38 patients with Basal Cell Carcinoma Nevus Syndrome (BCCNS). Solid clinical execution was demonstrated with the completion of a Phase 2b trial in BCCNS, confirming a low toxicity safety profile when compared to published data for other oncology drugs that inhibit the same pathway as a treatment for basal cell carcinoma (BCC) lesions.

INHIBITOR Therapeutics, Inc.

Similar companies